IC-MPGN and C3G are rare kidney diseases. In both diseases, an important part of the immune system known as the complement cascade is overactive, which results in the excessive breakdown of a protein called C3.1 These C3 breakdown products become trapped in the kidney, causing inflammation and damage to the organ.1
Although IC-MPGN is a distinct disease from C3G, the underlying cause and progression of the two diseases are remarkably similar.2,3 The signs and symptoms of IC-MPGN and C3G include blood in the urine (hematuria); dark foamy urine due to the presence of protein (proteinuria); edema (swelling), often in the legs, although any part of the body can be affected; high blood pressure; and decreased urine output.4
There are no medicines currently approved for IC-MPGN or C3G, so there is a substantial need for medicines that target the cause of the diseases. IC-MPGN and C3G can lead to kidney failure within five to 10 years of diagnosis, requiring these patients to go on dialysis or get a kidney transplant.5
Pegcetacoplan is a targeted C3 therapy under investigation for IC-MPGN and C3G. We believe pegcetacoplan may have the potential to target the underlying disease processes of IC-MPGN and C3G.
For clinical trial information, please email us at email@example.com.